From May chairman letter4 Jun 2026 11:39
P140 and Kapiglucagon, have the potential to support value creation over the period of the agreement.
Importantly, the successful fundraising extends the Company's cash runway to at least H2 2028*. This strong financial leverage enhances our ability to negotiate a P140 licensing agreement from a position of strength, while also providing the flexibility to accelerate the Kapiglucagon program and selectively invest in earlier-stage pipeline opportunities.
With the progress already underway, the Board believes 2026 will be a year of delivery, momentum, and success for ImmuPharma and its shareholders.